Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes

Lenalidomide and azacitidine each have activity in myelodysplastic syndromes (MDS) patients, where both microenvironment and cell-regulatory mechanisms contribute to disease pathogenesis. The objective of this multicenter, phase 2 expansion trial was to determine the efficacy and safety of combinati...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Sekeres, Mikkael A., Tiu, Ramon V., Komrokji, Rami, Lancet, Jeffrey, Advani, Anjali S., Afable, Manuel, Englehaupt, Ricki, Juersivich, Joyce, Cuthbertson, David, Paleveda, Jennifer, Tabarroki, Ali, Visconte, Valeria, Makishima, Hideki, Jerez, Andres, Paquette, Ronald, List, Alan F., Maciejewski, Jaroslaw P.
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Hematology 2012
Предметы:
Clinical Trials and Observations
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3525020/
https://ncbi.nlm.nih.gov/pubmed/22915641
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-06-434639
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы